A Phase II Study of Reduced Intensity Allogeneic Transplantation for Refractory Hodgkin Lymphoma
- To document the toxicity and feasibility of reduced-intensity conditioning regimen
comprising carmustine, etoposide, cytarabine, melphalan, and alemtuzumab followed by
allogeneic hematopoietic stem cell transplantation in patients with primary refractory
or relapsed Hodgkin lymphoma.
- To document the survival of patients treated with this regimen.
OUTLINE: This is a multicenter study.
- Conditioning regimen: Patients receive BEAM chemotherapy comprising carmustine IV over
2 hours on day -6, etoposide IV over ≥ 1 hour on days -5 to -2, cytarabine IV over 15
minutes twice daily on days -5 to -2, and melphalan IV on day -1. Patients also receive
alemtuzumab IV on days -5 to -1.
- Allogeneic hematopoietic stem cell transplantation (HSCT): Patients undergo allogeneic
HSCT on day 0.
- Graft-versus-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV (or
orally once tolerable) beginning on day -1 and continuing until day 60, followed by a
taper in the absence of GVHD.
- Donor lymphocyte infusion (DLI): Patients with mixed chimerism or stable residual
disease at 6 months after HSCT or disease progression or relapse at any time after HSCT
may receive DLI in the absence of GVHD.
After completion of study treatment, patients are followed periodically for 3 years.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Masking: Open Label, Primary Purpose: Treatment
Progression-free survival at 3 years
Karl Peggs, MD
University College London (UCL) Cancer Institute